4 registrations that name bifidobacterium lactis as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
All 4 registrations
RecruitingNCT06428422
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
No phase
Necmettin Erbakan University
About 100 people
Started Aug 12, 2024
In plain words A study of bifidobacterium lactis in people 19 to 90, run by Necmettin Erbakan University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 90. Conditions: Metastatic Non-small Cell Lung Cancer.
Volunteering to participate in the study.
Histologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC).
Patients must be in an advanced stage (incurable with surgery or radiotherapy) or have metastatic disease (Stage IV).
Male or female patients aged >18 years.
2 more inclusion criteria and the exclusion criteria are on the listing.
The aim of this study is to evaluate the effect of a probiotic supplement containing Bifidobacterium animalis lactis BL-04 on the clinical effectiveness of immunotherapy in patients diagnosed with metastatic non-small cell lung cancer who are receiving immunotherapy.
Where, as registered
No US site; Turkey (Türkiye) (1).
RecruitingNCT05791604
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
No phase
Children's Hospital of Fudan University
About 60 people
Started Apr 1, 2023
In plain words A study of bifidobacterium lactis in people 3 to 10, run by Children's Hospital of Fudan University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 10. Conditions: Prader-Willi Syndrome.
Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing.
Consistent with the diagnostic criteria for obesity.
Not participate in other research projects at present or three months before the research;
Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG; Prebiotics with galactomannan and oligofructose
Registered summary
Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07617181
Probiotics Supplementation for Neurodevelopment in Preterm Infants
No phase
Fudan University
About 116 people
Starts Jun 2026 (estimated)
In plain words A study of bifidobacterium lactis in people 23 weeks to 25 weeks, run by Fudan University. It plans to enroll about 116 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 23 weeks to 25 weeks. Conditions: Premature Birth; Neurodevelopmental Disorders; Dysbiosis.
Preterm infants with a gestational age between 28 and 37 weeks (inclusive of 28 weeks)
Documented history of neonatal intravenous antibiotic exposure for at least 5 consecutive days during the neonatal period (e.g., in the NICU).
Corrected age of 6 months ± 7days at the time of enrollment.
No systemic antibiotic usage within 14 days prior to screening.
1 more inclusion criterion and the exclusion criteria are on the listing.
The purpose of this randomized controlled trial is to evaluate the effect of daily supplementation with a probiotic mixture on the neurodevelopmental outcomes of preterm infants with a history of neonatal antibiotic exposure. The intervention lasts for 6 months. The study hypothesizes that early gut microbiota remodeling via exogenous probiotics can improve neurodevelopment. The primary outcome is assessed by the Gesell Developmental Schedules or the Ages \& Stages Questionnaires (ASQ-3). The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07773012
Efficacy of Bifidobacterium Animalis Subsp. Lactis in the Treatment of Indirect Hyperbilirubinemia in Term Neonates
No phase
Can Tho University of Medicine and Pharmacy
About 90 people
Starts Aug 1, 2026 (estimated)
In plain words A study of bifidobacterium lactis in people up to 28 days, run by Can Tho University of Medicine and Pharmacy. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people up to 28 days. Conditions: Indirect Hyperbilirubinemia.
Age from 0-28 days.
Gestational age 37-42 weeks.
Diagnosed with indirect hyperbilirubinemia according to the AAP 2022 guidelines.
Eligible for phototherapy based on serum total bilirubin levels
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Bifidobacterium animalis subsp. lactis; Standard Phototherapy
Registered summary
This study aims to evaluate the effectiveness of adjunctive oral Bifidobacterium animalis subsp. lactis in term neonates with indirect hyperbilirubinemia receiving phototherapy. The study will compare the effects of adjunctive probiotics plus standard phototherapy with standard phototherapy alone on the duration of phototherapy, length of hospital stay, serum total bilirubin reduction, phototherapy-related adverse events, and hospital readmission after discharge.
Where, as registered
No US site; Vietnam (1).
ClinicalTrials.gov lists 39 open registrations for this search, including ones where bifidobacterium lactis is not a study arm or that are past the 4 we keep. Search them on ClinicalTrials.gov (opens in new tab).